Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells.

ABSTRACT: Impaired immunity in patients with late-stage cancer is not limited to antitumor responses, as demonstrated by poor vaccination protection and high susceptibility to infection^1-3. This has been largely attributed to chemotherapy-induced impairment of innate immunity, such as neutropenia², whereas systemic effects of tumors on hematopoiesis and adoptive immunity remain incompletely understood. Here we observed anemia associated with severe deficiency of CD8⁺ T cell responses against pathogens in treatment-naive mice bearing large tumors. Specifically, we identify CD45⁺ erythroid progenitor cells (CD71⁺TER119⁺; EPCs) as robust immunosuppressors. CD45⁺ EPCs, induced by tumor growth-associated extramedullary hematopoi

SUBMITTER: Zhao L 

PROVIDER: S-EPMC6211844 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature